Immunomodulatory News and Research

RSS

Estradiol appears to help in female SARS-CoV-2 infection

A new study published on the preprint server medRxiv in August 2020 shows that the risk of infection is high for pre-menopausal women but the risk of death is much higher for men in the same age group and throws light on the protective nature of estradiol therapy in post-menopausal women.

26 Aug 2020

Developing a blood test for prostate cancer

Professor Pockley among researchers from the John van Geest Cancer Research Centre have recently developed a blood test for the detection of prostate cancer.

13 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19

New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.

5 Aug 2020

Can Vitamin D help combat the coronavirus?

In a new report published in The Lancet, a team of researchers discussed the possibility that vitamin D could offer protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The meta-analyses of randomized controlled trials performed from 2007 to 2020.

4 Aug 2020

Anti-inflammatory Tetracycline activity may modulate COVID-19 severity

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to attack the human airway epithelium primarily. In severely affected patients, the illness progresses to hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS). The latter is treatable mainly by supportive management.

30 Jul 2020

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

In a recent bioRxiv* study, UK researchers used interleukin modules to investigate the pathology of coronavirus disease (COVID-19).

27 Jul 2020

Vitamin D could help suppress excessive T cell-mediated lung inflammation in severe COVID-19

As COVID-19 continues to spread over the world scientists continue to seek the reasons for the difference in disease severity from person to person.

22 Jul 2020

A multi-omics single cell analysis on COVID-19

Now, a new study published on the preprint server medRxiv aims to analyze the immune response over time, using multi-omics in the study of a single cell.

21 Jul 2020

Selective statins may reduce SARS-CoV-2 cell entry and inhibit infection

Statins are a class of drugs often used to control high cholesterol levels in obesity. Now, a study published on the preprint server medRxiv* in July 2020 suggests that statins do not aggravate the risk of COVID-19 infection and may have a small beneficial effect in some cases.

16 Jul 2020

Investigational antidepressant PT150 shows antiviral activity against SARS-CoV-2

In a recent bioRxiv study, an ad hoc multi-institutional research team from the US shows that a novel hormone receptor modulator PT150 has unique and possibly additive antiviral and immunomodulatory effects – highlighting its potential role in the treatment and prophylaxis of coronavirus disease (COVID-19).

14 Jul 2020

COVID-19 – researchers sum up the “Tsunami” of information

The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection leading to COVID-19 is a raging pandemic across the world at present. It has infected 13 million and killed 571,000 individuals around the world as of today. The infection was first reported in Wuhan, Hubei Province of China in late December 2019.

13 Jul 2020

Fatalities are very rare in children with COVID-19

Children with COVID-19 generally experience a mild disease and fatalities are very rare, according to a study of 582 patients from across Europe published today in The Lancet Child & Adolescent Health journal.

26 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

Study assesses impact of anti-SARS-CoV-2 convalescent plasma in COVID-19 disease

The current COVID-19 pandemic is still very much active in most parts of the world. In the absence of effective antiviral drugs or vaccines, scientists are studying the use of blood plasma from convalescent COVID-19 patients, banking on its neutralizing antibody content.

25 Jun 2020

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Critical Path Institute announced today that its Transplant Therapeutics Consortium has received a positive response to its Letter of Intent from the U.S. Food and Drug Administration detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program.

17 Jun 2020

Antisense Therapeutics: Poster presentation on the Muscular Dystrophy Association Virtual Conference 2020 website

Antisense Therapeutics, an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association Virtual 2020 Conference website.

15 Jun 2020